Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement
Hannes Hagström,Hannes Hagström,Leon A. Adams,Alina M. Allen,Christopher D. Byrne,Christopher D. Byrne,Yoosoo Chang,Henning Grønbæk,Mona H Ismail,Peter Uhd Jepsen,Fasiha Kanwal,Jennifer R. Kramer,Jeffrey V. Lazarus,Michelle T. Long,Rohit Loomba,Philip N. Newsome,Philip N. Newsome,Ian A. Rowe,Seungho Ryu,Jörn M. Schattenberg,Marina Serper,Nick Sheron,Tracey G. Simon,Elliot B. Tapper,Sarah H. Wild,Vincent Wai-Sun Wong,Yusuf Yilmaz,Shira Zelber-Sagi,Fredrik Åberg +28 more
TLDR
The lack of consensus on which International Classification of Disease (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies as discussed by the authors.About:
This article is published in Hepatology.The article was published on 2021-01-23 and is currently open access. It has received 60 citations till now.read more
Citations
More filters
Journal ArticleDOI
Advancing the global public health agenda for NAFLD: a consensus statement.
Jeffrey V. Lazarus,Henry E. Mark,Quentin M. Anstee,Juan Pablo Arab,Rachel L. Batterham,Laurent Castera,Helena Cortez-Pinto,Javier Crespo,Kenneth Cusi,M. Ashworth Dirac,Sven Francque,Jacob George,Hannes Hagström,Terry T-K Huang,Mona H Ismail,Achim Kautz,Shiv Kumar Sarin,Rohit Loomba,Veronica Miller,Philip N. Newsome,Michael Ninburg,Ponsiano Ocama,Vlad Ratziu,Mary E. Rinella,Diana Romero,Manuel Romero-Gómez,Jörn M. Schattenberg,Emmanuel Tsochatzis,Emmanuel Tsochatzis,Luca Valenti,Luca Valenti,Vincent Wai-Sun Wong,Yusuf Yilmaz,Zobair M. Younossi,Shira Zelber-Sagi +34 more
TL;DR: In this paper, a global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved.
Journal ArticleDOI
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
TL;DR: The European Association for the Study of the Liver (EASL) proposed a framework for the principal actions required to improve liver health in Europe as mentioned in this paper , which can serve as a powerful mechanism for improving liver care in Europe.
Journal ArticleDOI
Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease
TL;DR: In this article , the authors evaluated the impact of ACEI/ARB use on the risk of liver cancer and cirrhosis complications in patients with NAFLD and found that ACEI treatment was associated with a lower risk of LREs.
Journal ArticleDOI
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
TL;DR: SGLT-2 inhibitors, and possibly GLP-1 RA, may be associated with a decreased incidence of NAFLD and hepatic transaminase elevation among patients with type 2 diabetes.
Journal ArticleDOI
Risk of cardiovascular disease and loss in life expectancy in NAFLD
TL;DR: Examination of CVD risk and life expectancy in patients with NAFLD compared with the general population found no change in either risk or life expectancy.
References
More filters
Journal ArticleDOI
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Michael Charlton,Kenneth Cusi,Mary E. Rinella,Stephen A. Harrison,Elizabeth M. Brunt,Arun J. Sanyal +8 more
TL;DR: This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.
Journal ArticleDOI
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
Giulio Marchesini,Christopher P. Day,Jean-François Dufour,Ali Canbay,Valerio Nobili,Vlad Ratziu,Herbert Tilg,Michael Roden,Amalia Gastaldelli,Hannele Yki-Järvinen,Fritz Schick,Roberto Vettor,Gema Frühbeck,Lisbeth Mathus-Vliegen +13 more
TL;DR: The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.
Journal ArticleDOI
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt,Hannes Hagström,Patrik Nasr,Mats Fredrikson,Per Stål,Stergios Kechagias,Rolf Hultcrantz +6 more
TL;DR: NAFLD patients have increased risk of death, with a high risk ofdeath from cardiovascular disease and liver‐related disease, and the NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease‐specific mortality.
Journal ArticleDOI
Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies
Ivan Diamond,Robert C. Grant,Brian M. Feldman,Paul B. Pencharz,Simon C. Ling,Aideen M. Moore,Paul W. Wales +6 more
TL;DR: Investigation of how consensus is operationalized in Delphi studies and the role of consensus in determining the results of these studies finds definitions of consensus vary widely and are poorly reported.
Related Papers (5)
Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Anna-Maria Hoffmann-Vold,Toby M. Maher,Edward E Philpot,Ali Ashrafzadeh,Rafic Barake,Simone Barsotti,Cosimo Bruni,Paolo Carducci,Patricia Carreira,Ivan Castellví,Francesco Del Galdo,Jörg H W Distler,Ivan Foeldvari,Paolo Fraticelli,Peter M. George,Bridget Griffiths,Alfredo Guillén-Del-Castillo,Abdul Monem Hamid,Rudolf Horváth,Michael Hughes,Michael Kreuter,Florentine Moazedi-Fuerst,Jacek Olas,Suman Paul,Cinzia Rotondo,Manuel Rubio-Rivas,Andrei Seferian,Andrei Seferian,Michal Tomcik,Yurdagul Uzunhan,Ulrich A. Walker,Ewa Więsik-Szewczyk,Oliver Distler +32 more
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Amanda C. Guidon,Leeann B Burton,Bart K Chwalisz,James M. Hillis,Teilo H Schaller,Anthony A. Amato,Allison Betof Warner,Priscilla K. Brastianos,Tracey A. Cho,Stacey L. Clardy,Justine V. Cohen,Jorg Dietrich,Michael Dougan,Christopher T. Doughty,Divyanshu Dubey,Jeffrey M. Gelfand,Jeffrey T. Guptill,Douglas B. Johnson,Vern C. Juel,Robert Kadish,Noah Kolb,Nicole R. LeBoeuf,Jenny J. Linnoila,Andrew L. Mammen,Maria Martinez-Lage,Meghan J. Mooradian,Jarushka Naidoo,Jarushka Naidoo,Tomas G. Neilan,David A. Reardon,Krista M. Rubin,Bianca Santomasso,Ryan J. Sullivan,Nancy Wang,Karin Woodman,Leyre Zubiri,William C Louv,Kerry L. Reynolds +37 more